Treatment of metastatic malignant melanoma
E Atallah, L Flaherty - Current treatment options in oncology, 2005 - Springer
Opinion statement The rapid increase in incidence of malignant melanoma has not been
associated with better therapeutic options over the years. Single-agent chemotherapy or …
associated with better therapeutic options over the years. Single-agent chemotherapy or …
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised …
…, KA Kreuzer, LA Godley, E Atallah… - The lancet …, 2016 - thelancet.com
Background Hypomethylating drugs are the standard treatment for patients with high-risk
myelodysplastic syndromes. Survival is poor after failure of these drugs; there is no approved …
myelodysplastic syndromes. Survival is poor after failure of these drugs; there is no approved …
Quality of life and long-term therapy in patients with chronic myeloid leukemia
KE Flynn, E Atallah - Current hematologic malignancy reports, 2016 - Springer
Since the development of imatinib and other tyrosine kinase inhibitors (TKIs), the prognosis
for patients with chronic myeloid leukemia (CML) has markedly improved, such that most …
for patients with chronic myeloid leukemia (CML) has markedly improved, such that most …
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia
E Atallah, J Cortes, S O'Brien, S Pierce… - Blood, The Journal …, 2007 - ashpublications.org
The rates of expected serious adverse events in patients with acute leukemia on chemotherapy
far exceed those in patients with solid tumors. Regulatory authorities require similar …
far exceed those in patients with solid tumors. Regulatory authorities require similar …
Management of myeloproliferative neoplasms in the molecular era: from research to practice
K Pettit, A Rezazadeh, EL Atallah… - American Society of …, 2022 - ascopubs.org
The 1960 discovery of the Philadelphia chromosome in chronic myeloid leukemia (CML)
marked the beginning of the modern genomic era of oncology. In the following years, the …
marked the beginning of the modern genomic era of oncology. In the following years, the …
Congestive heart failure is a rare event in patients receiving imatinib therapy
E Atallah, JB Durand, H Kantarjian… - Blood, The Journal of …, 2007 - ashpublications.org
A recent preclinical study suggested that imatinib may be cardiotoxic in some patients. We
reviewed all reported serious adverse events of cardiac adverse events occurring in patients …
reviewed all reported serious adverse events of cardiac adverse events occurring in patients …
[HTML][HTML] Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic …
…, Y Zhang, MR Velasco, R Gaur, E Atallah… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
… Velasco, Rakesh Gaur, Ehab Atallah, Eyal C. Attar, Elina K. Cook, Alyssa H. … Sekeres,
Megan Othus, Diane Roulston, Anna Moseley, Aziz Nazha, Yanming Zhang, Ehab Atallah …
Megan Othus, Diane Roulston, Anna Moseley, Aziz Nazha, Yanming Zhang, Ehab Atallah …
[HTML][HTML] Treatment-free remission: the new goal in CML therapy
E Atallah, K Sweet - Current Hematologic Malignancy Reports, 2021 - Springer
Purpose of Review Treatment-free remission (TFR) is considered one of the main goals of
therapy in patients with CML. Our goal in this paper is to review the current data on TFR, and …
therapy in patients with CML. Our goal in this paper is to review the current data on TFR, and …
Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
…, S Strickland, ES Wang, E Atallah… - Blood, The Journal …, 2022 - ashpublications.org
The phase 3 ADMIRAL (NCT02421939; Study ID: 2215-CL-0301) trial showed superior
overall survival in patients with relapsed/refractory FLT3-mutation–positive acute myeloid …
overall survival in patients with relapsed/refractory FLT3-mutation–positive acute myeloid …
Imatinib and Panax Ginseng: A Potential Interaction Resulting in Liver Toxicity
…, AN Ananthakrishnan, E Atallah - Annals of …, 2010 - journals.sagepub.com
OBJECTIVE: To report a case of imatinib-induced hepatotoxicity after concurrent ginseng
ingestion in a patient with chronic myelogenous leukemia (CML). CASE SUMMARY: A 26-year-…
ingestion in a patient with chronic myelogenous leukemia (CML). CASE SUMMARY: A 26-year-…